Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ronopterin in Moderate and Severe Traumatic Brain Injury
NCT02794168Phase 3Completed
- Sponsor
- Vasopharm
- Start
- Jun 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of ronopterin in traumatic brain injury (TBI) (2 arms), sponsored by Vasopharm. Primary endpoint: extended Glasgow Outcome Scale at 6 months. Started Jun 2016; status: completed.
02
Drugs
ronopterin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02794168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794168.